We're excited to announce that our Head of Business Development, Dr. Michelle Chen, and Gloria Chen, Vice President of R&D Team II, will be attending BIO International Convention 2026 in San Diego! 🌊 Our key assets include: AC-203 – Late-stage asset for the rare dermatological disease Epidermolysis Bullosa Simplex (EBS) AC-1101 – Topical JAK inhibitor for autoimmune skin disorders, including Alopecia Areata NORA-520 – Novel CNS asset targeting unmet needs in Major Depressive Disorder (MDD) We look forward to connecting with partners and exploring collaboration opportunities across rare diseases, dermatology, and CNS. 📅 June 22–25, 2026 📍 San Diego, CA #BIO2026 #BIO26 #Biotech #RareDisease #Dermatology #CNS #EB

TWi Biotechnology today announced the completion of patient enrollment in its global Phase 2/3 EBShield study of AC-203 for epidermolysis bullosa simplex (EBS). A total of 81 patients have been enrolled across 37 clinical sites in 19 countries, reflecting the global scope of this randomized, double-blind, vehicle-controlled study. With enrollment now completed, the study will continue to progress toward data analysis and the anticipated top-line efficacy readout by the end of 2026. Upon successful results, the company plans to initiate pre-NDA discussions with regulatory authorities to support future registration. For more details on the completion of enrollment in the global Phase 2/3 EBShield study of AC-203 for EBS, please visit our official announcement at shorturl.at/xOwmi

Every day is an uphill battle for 13-year-old Jasmine Ritchie, who has a rare skin condition called Epidermolysis Bullosa, also known as butterfly skin, which causes her skin to blister and tear at the slightest touch. Jasmine's mum, Anna, and Grandad Robert took on their own challenge to raise money for those living with the skin disorder by climbing Mount Kilimanjaro. Anna recalls the experience as Graeme Souness explains why raising awareness and money is so important. @susannareid100 | @edballs | @CharityDEBRA

We are excited to officially join X and look forward to engaging with the global biotech and EB communities! #RareDisease #Dermatology #505b2 #EBS #Epidermolysisbullosa